Aaron Snell

Aaron Snell

Auto-generated profile, based on publicly available information

Aaron Snell

Department of Ophthalmology, University of Florida, Gainesville, FL 32610, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2023 in Science Advances
Verified
Journal Article
Open access
YWYixiao Wang
Yixiao Wang
ASAaron Snell
Aaron Snell
FDFrank M. Dyka
Frank M. Dyka
ECElizabeth R. Colvin
Elizabeth R. Colvin
CICristhian J. Ildefonso
Cristhian J. Ildefonso
ELEkaterina Lobanova
Ekaterina Lobanova
Proteasomes are the central proteolytic machines that are critical for breaking down most of the damaged and abnormal proteins in human cells. Although universally applicable drugs are not yet available, the stimulation of proteasomal activity is being analyzed as a proof-of-principle strategy to increase cellular resistance to a broad range of proteotoxic stressors. These approaches have included the stimulation of proteasomes through the overexpression of individual proteasome subunits, phosphorylation, or conformational changes induced by small molecules or peptides. In contrast to these approaches, we evaluated a transcription-driven increase in the total proteasome pool to enhance the proteolytic capacity of degenerating retinal neurons. We show that overexpression of nuclear factor erythroid-2-like 1 (Nfe2l1) transcription factor stimulated proteasome biogenesis and activity, improved the clearance of the ubiquitin-proteasomal reporter, and delayed photoreceptor neuron loss in a preclinical mouse model of human blindness caused by misfolded proteins. The findings highlight Nfe2l1 as an emerging therapeutic target to treat neurodegenerative diseases linked to protein misfolding.